Eisai to present new lecanemab and tau-targeting data at AAIC 2026

The company’s presence at the July 12–15 conference centers on long-term clinical data, specifically regarding the LEADER study, which tracks lecanemab’s efficacy and patient outcomes three years post-approval in diverse U.S. clinical environments. Presentations will offer the first insights into at-home subcutaneous administration and maintenance dosing strategies, providing a clearer picture of how the drug functions outside of controlled trial settings.

Beyond lecanemab, Eisai is highlighting progress with etalanetug (E2814), an investigational antibody designed to inhibit the spread of tau seeds in the brain. Researchers will share findings from a Phase 2 trial where etalanetug is used alongside lecanemab, testing a dual-target approach to neurodegeneration. According to Lynn D. Kramer, Chief Clinical Officer at Eisai’s Deep Human Biology Learning division, the data reflects a broader shift toward personalized care, prioritizing patient choice in administration and early intervention strategies.